Denmark's Zealand Pharma and Boehringer Ingelheim's experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial on Wednesday.

Source: https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Roche-enters-obesity-drugs-race-with-2-7-bln-Carmot-deal-45493914/?utm_medium=RSS&utm_content=20231204

Investors are also eyeing Inc.’s experimental danuglipron after a mid-stage study yielded positive results.

Source: https://fortune.com/well/2023/05/24/noom-med-weight-loss-injectables-ozempic-wegovy-mounjaro/

Nearly a year ago, Rivus Pharmaceuticals unveiled a $132 million Series B round of financing to support mid-stage clinical development of drugs it calls controlled metabolic accelerators.

Source: https://medcitynews.com/2023/08/still-hungry-for-new-obesity-meds-novo-nordisk-makes-another-ma-deal/

Pfizer, aiming for a resurgence in revenue after pandemic-related sales decline, is also focusing on an obesity pill currently in mid-stage study.

Source: http://davidsonian.com/2023/11/28/novo-nordisk-and-eli-lilly-develop-pill-versions-of-weight-loss-drugs-posing-cost-and-side-effect-concerns/